About Eli Lilly and Company
https://www.lilly.comEli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
CEO
David A. Ricks
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 1997-10-16 | Forward | 2:1 |
| 1995-12-21 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 1,099
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 17
Price Target
Institutional Ownership
LILLY ENDOWMENT INC
Shares:95.49M
Value:$102.49B
VANGUARD GROUP INC
Shares:80.96M
Value:$86.89B
BLACKROCK INC.
Shares:65.86M
Value:$70.68B
Summary
Showing Top 3 of 4,823
About Eli Lilly and Company
https://www.lilly.comEli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $17.6B ▲ | $6.86B ▲ | $5.58B ▼ | 31.72% ▼ | $6.22 ▼ | $7.88B ▲ |
| Q2-2025 | $15.56B ▲ | $5.98B ▲ | $5.66B ▲ | 36.38% ▲ | $6.3 ▲ | $7.5B ▲ |
| Q1-2025 | $12.73B ▼ | $5.1B ▼ | $2.76B ▼ | 21.68% ▼ | $3.07 ▼ | $4.16B ▼ |
| Q4-2024 | $13.53B ▲ | $5.33B ▲ | $4.41B ▲ | 32.59% ▲ | $4.91 ▲ | $5.75B ▲ |
| Q3-2024 | $11.44B | $4.72B | $970.3M | 8.48% | $1.08 | $2.25B |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $9.91B ▲ | $114.94B ▲ | $91.08B ▲ | $23.79B ▲ |
| Q2-2025 | $3.55B ▲ | $100.92B ▲ | $82.57B ▲ | $18.27B ▲ |
| Q1-2025 | $3.22B ▼ | $89.39B ▲ | $73.54B ▲ | $15.76B ▲ |
| Q4-2024 | $3.42B ▼ | $78.71B ▲ | $64.44B ▲ | $14.19B ▼ |
| Q3-2024 | $3.52B | $75.61B | $61.29B | $14.24B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $5.58B ▼ | $8.84B ▲ | $-2.98B ▼ | $531M ▲ | $6.42B ▲ | $8.61B ▲ |
| Q2-2025 | $5.66B ▲ | $3.09B ▲ | $-1.83B ▲ | $-1.24B ▼ | $282.6M ▲ | $1.28B ▲ |
| Q1-2025 | $2.76B ▼ | $1.67B ▼ | $-3.35B ▼ | $1.38B ▲ | $-175.1M ▼ | $-1.6B ▼ |
| Q4-2024 | $4.41B ▲ | $2.47B ▼ | $-1.92B ▲ | $-225.4M ▼ | $-100.6M ▼ | $726.6M ▲ |
| Q3-2024 | $970.3M | $3.71B | $-4B | $211.3M | $145.4M | $-458.9M |
Revenue by Products
| Product | Q3-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Cardiometabolic Health | $7.41Bn ▲ | $9.21Bn ▲ | $11.34Bn ▲ | $13.18Bn ▲ |
 Immunology | $1.19Bn ▲ | $1.09Bn ▼ | $1.26Bn ▲ | $1.36Bn ▲ |
 Neuroscience | $470.00M ▲ | $270.00M ▼ | $340.00M ▲ | $320.00M ▼ |
 Oncology | $2.56Bn ▲ | $1.95Bn ▼ | $2.41Bn ▲ | $2.41Bn ▲ |
 Other Product Total | $260.00M ▲ | $210.00M ▼ | $200.00M ▼ | $340.00M ▲ |
Revenue by Geography
| Region | Q4-2024 | Q2-2025 | Q3-2025 | Q1-2025 |
|---|---|---|---|---|
 CHINA | $430.00M ▲ | $470.00M ▲ | $560.00M ▲ | $450.00M ▼ |
 Europe | $2.45Bn ▲ | $2.57Bn ▲ | $3.50Bn ▲ | $2.39Bn ▼ |
 JAPAN | $560.00M ▲ | $520.00M ▼ | $550.00M ▲ | $400.00M ▼ |
 NonUS | $1.06Bn ▲ | $1.18Bn ▲ | $1.69Bn ▲ | $1.00Bn ▼ |
 UNITED STATES | $9.03Bn ▲ | $10.81Bn ▲ | $11.30Bn ▲ | $8.49Bn ▼ |
CEO
David A. Ricks
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 1997-10-16 | Forward | 2:1 |
| 1995-12-21 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 1,099
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 17
Price Target
Institutional Ownership
LILLY ENDOWMENT INC
Shares:95.49M
Value:$102.49B
VANGUARD GROUP INC
Shares:80.96M
Value:$86.89B
BLACKROCK INC.
Shares:65.86M
Value:$70.68B
Summary
Showing Top 3 of 4,823